International Biotechnol... Share Discussion Threads

[davebowler] 27/9/2013 11:50

Date NAV Pence Thursday 26 Sep Ex Income 334.66

[davebowler] 25/9/2013 12:52

Portfolio Update The Board of International Biotechnology Trust plc (the "Company") notes two unquoted portfolio events. Today the unquoted portfolio company, Ophthotech Corporation, has listed on the NASDAQ Global Select market - ticker OPHT. The Company owns 209,902 Common Stock, which are locked up and may not be traded for 180 days. Applying the Initial Public Offering price of $22 to the Company's ownership and incorporating a 2% liquidity discount to reflect the lock up terms, results in an increase in Net Asset Value of £1.2m or 2.1 pence per share above the valuation released on 24 September 2013. In addition, the unquoted portfolio company TransEnterix reverse merged with the Over The Counter Bulletin Board (OTCBB:SFES) traded SafeStitch Medical on 4 September 2013 alongside a $30m fund raising. These shares are thinly traded and so no change in valuation was made when the reverse merger took place. Our Manager has been following the trading in the shares since the merger and the 4,445,411 SafeStitch Medical shares owned by the Company are now valued at $0.40 a share, based upon the price per share of the $30m fund raising. This values the holding at £1.1m, an increase of £0.3m or 0.6 pence per share above the valuation released on 24 September 2013. Due to the thinly traded nature of the OTC market, this holding will remain in the unquoted portfolio.

[philo124] 12/9/2013 08:38

Topped up 33%.

[davebowler] 11/9/2013 15:57

Date NAV Pence Tuesday 10 Sep Ex Income 328.59 ------------ -------

[philo124] 09/9/2013 11:49

Yep, this and other Bio/Tech IT's have been a good place to be.

[davebowler] 09/9/2013 11:45

Date NAV Pence Friday 06 Sep Ex Income 323.38

[davebowler] 09/9/2013 11:27

hxxps://www.fidelity.co.uk/professional/perspectives/details.page?id=/templatedata/perspectives/article/data/undervaluing-innovation-in-pharma

[philo124] 02/9/2013 11:57

Yep; great long term hold and balance to divi stocks.

[davidbh] 02/9/2013 11:53

V. impressive cv

[davebowler] 02/9/2013 09:48

International Biotechnology Trust plc Staff Change at Investment Manager The Board of International Biotechnology Trust plc (the "Company") notes that the Company's Investment Manager, SV Life Sciences Managers LLP, has appointed Carl Harald Janson as Investment Manager, who will start with effect from today Monday, 2 September 2013. Carl Harald will be supported by Ailsa Craig to run the quoted side of the portfolio, and managing partner Kate Bingham will continue to manage the unquoted side of the portfolio. Among Carl Harald's many achievements, the outstanding performance of the Carnegie Biotechnology Fund stands out as a key highlight. During his six years and four months as its Principal Fund Manager, Carl Harald was recognised by Bloomberg as the top performing biotech fund manager worldwide. During this time period, the Carnegie Biotechnology Fund had a total return of 54% (USD) while the NASDAQ Biotechnology Index returned minus 26% (USD), a relative outperformance of approximately 80% (USD). Carl Harald is excited to be focusing on the International Biotechnology Trust portfolio, and looks forward to the challenge of again delivering excellent long term performance in an area he is passionate about. Carl Harald qualified as a medical doctor in 1981, completed his PhD in 1990 at the Karolinska Institutet, and qualified as Certified European Financial Analyst from the Stockholm School of Economics in 1999. In 1992 he joined Astra Arcus where he held various positions including Director for Preclinical Research and Development. In 1997 Carl Harald began to combine his medical and pharmaceutical industry insights with finance by working as a Senior Financial Analyst for Hagstromer & Qviberg and then Danske Securities. In 2000 he gained a role as Senior Portfolio Manager and Principal Fund Manager of the Carnegie Biotechnology Fund at Carnegie Investment Bank in Stockholm. Carl Harald responsibilities at Carnegie Investment Bank also included Fund Manager of the Carnegie Medical Fund, and the Carnegie BiotechBridge Fund. In 2008 Carl Harald was appointed Investment Manager at Karolinska Development in Stockholm, and has served as a member of the board of various Swedish biotechnology companies including Akinion Pharmaceuticals, Axelar, Aprea, Oncopeptides, and Clanotech. Since 2012 he held various chief executive roles for the Karolinska Development portfolio companies.

[philo124] 06/8/2013 18:40

Pretty good progress.

[davebowler] 06/8/2013 09:56

Date NAV Pence Friday 02 Aug Ex Income 325.85

[davebowler] 30/7/2013 09:38

NAV Friday 26 Jul 317.10

[davebowler] 24/7/2013 12:06

Date NAV Pence 23 Jul Ex Inc. 313.06 p

[protean] 17/7/2013 08:56

Prognosis: Healthy earnings for pharma, biotech www.cnbc.com/id/100890557

[protean] 14/7/2013 10:49

The sector is on a roll: dealbook.nytimes.com/2013/07/11/biotech-companies-surge-as-investors-flock-to-them/

[philo124] 08/7/2013 16:00

Just topped a little for SIPP a/c.

[philo124] 04/7/2013 23:41

Still here.

[davebowler] 21/6/2013 10:50

NAV Wednesday 19 Jun Ex Income 280.75

[davebowler] 24/5/2013 13:54

http://uk.advfn.com/news/UKREG/2013/article/57716789